Physician profile
Sofia N Hanger
NPI 1780942755
$14,379.93
in general payments reported to CMS, 2019-2025
30 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,079 · 2022: $2,410 · 2023: $3,379 · 2024: $3,152 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,745 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,745.43 |
| Education | $144.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,917.90 | 2021-2025 | |
| Janssen Biotech, INC. | $1,443.26 | 2021-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $1,088.50 | 2021-2025 | |
| Galderma Laboratories, L.P. | $949.42 | 2021-2025 | Aklief, Oracea, Nemluvio |
| Sun Pharmaceutical Industries INC. | $917.98 | 2021-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $867.90 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Incyte Corporation | $836.69 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $783.51 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $759.63 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $712.46 | 2021-2025 | |
| Journey Medical Corporation | $684.14 | 2021-2023 | |
| Ucb, INC. | $629.16 | 2021-2025 | Cimzia, Bimzelx |
| Leo Pharma INC. | $567.63 | 2021-2025 | Adbry |
| Lilly USA, LLC | $407.82 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $382.17 | 2021-2025 | Otezla, Enbrel, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $344.16 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $324.44 | 2022-2025 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $187.91 | 2022-2025 | |
| Epi Health, LLC | $124.12 | 2021-2022 | |
| Dermavant Sciences, INC. | $70.19 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $69.71 | 2021 | |
| Organon LLC | $64.36 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $58.91 | 2022 | |
| Vyne Pharmaceuticals INC. | $35.66 | 2021 | |
| Revance Therapeutics, INC. | $34.73 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.31 | 2024 | Spevigo |
| Fresenius Kabi USA, LLC | $28.95 | 2023 | Idacio |
| Verrica Pharmaceuticals INC. | $22.19 | 2023 | Ycanth |
| Ani Pharmaceuticals, INC. | $21.20 | 2022 | |
| Almirall LLC | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Hanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.